NDA (New Drug Application)
ANDA (Generic Application)
Track protection status across key markets to assess launch feasibility.
It is formulated by 1 pharmaceutical company such as GILEAD SCIENCES INC. It is marketed under 2 brand names, including SUNLENCA, YEZTUGO. Available in 2 different strengths, such as EQ 463.5MG BASE/1.5ML (EQ 309MG BASE/ML), EQ 300MG BASE, and administered through 2 routes including SOLUTION;SUBCUTANEOUS, TABLET;ORAL.
API availability: Loading API feasibility...
Licensing: 1 potential partnersUS Launch window: Loading launch window...
Stay ahead with worldwide patent expiry and latest updates.
FDA approval history for this ingredient
Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.
Key expiration dates for US patents covering this ingredient
Stay ahead with worldwide patent expiry insights, market data, and research updates.
Latest drug strengths approved by FDA
| Strength | Route of Administration | Companies | Latest Approval Date |
|---|
Patents approved by the FDA for the ingredient
|
|
Patent Number | Publication Date | Legal Status | Patent Expiry Date | |
|---|---|---|---|---|---|
| {"application_id":"110603","ingredient":"LENACAPAVIR SODIUM","trade_name":"SUNLENCA","family_id":"e874ace7c83441e3afb3","publication_number":"US9951043B2","cleaned_patent_number":"9951043","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2034-02-28","publication_date":"2018-04-24","legal_status":"Granted"} | US9951043B2 Molecular Formulation | 24 Apr, 2018 | Granted | 28 Feb, 2034 | |
| {"application_id":"110596","ingredient":"LENACAPAVIR SODIUM","trade_name":"SUNLENCA","family_id":"f97a459dbc554b1db205","publication_number":"US10071985B2","cleaned_patent_number":"10071985","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2037-08-17","publication_date":"2018-09-11","legal_status":"Granted"} | US10071985B2 Molecular Formulation | 11 Sep, 2018 | Granted | 17 Aug, 2037 | |
| {"application_id":"118976","ingredient":"LENACAPAVIR SODIUM","trade_name":"SUNLENCA","family_id":"f97a459dbc554b1db205","publication_number":"US10654827B2","cleaned_patent_number":"10654827","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2037-08-17","publication_date":"2020-05-19","legal_status":"Granted"} | US10654827B2 | 19 May, 2020 | Granted | 17 Aug, 2037 | |
| {"application_id":"110668","ingredient":"LENACAPAVIR SODIUM","trade_name":"SUNLENCA","family_id":"974f260ce2854500bc18","publication_number":"US11267799B2","cleaned_patent_number":"11267799","drug_product_flag":"-","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2038-08-16","publication_date":"2022-03-08","legal_status":"Granted"} | US11267799B2 Molecular | 08 Mar, 2022 | Granted | 16 Aug, 2038 | |
| {"application_id":"38225","ingredient":"LENACAPAVIR SODIUM","trade_name":"SUNLENCA","family_id":"cc9555e5e05a479ea874","publication_number":"US11944611B2","cleaned_patent_number":"11944611","drug_product_flag":"-, Y","drug_substance_flag":"-, Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2041-08-28","publication_date":"2024-04-02","legal_status":"Granted"} | US11944611B2 | 02 Apr, 2024 | Granted | 28 Aug, 2041 |
Latest clinical trials and research studies for this ingredient
| NCT ID | Title | Status | Phase | Conditions | Start Date | Completion Date |
|---|
Manufacturing Locations
Unlock access to all suppliers of Lenacapavir Sodium
Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.